Open-label onderzoek om de veiligheid en werkzaamheid van CABA-201 te evalueren bij proefpersonen met actieve idiopathische inflammatoire myopathie
Een fase 1/2, open-label onderzoek om de veiligheid en werkzaamheid van autologe CD19-specifieke chimere antigeenreceptor-T-cellen (CABA-201) te evalueren bij proefpersonen met actieve idiopathische inflammatoire myopathie
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Cabaletta Bio
- Telefoonnummer: 4444 267-759-3100
- E-mail: clinicaltrials@cabalettabio.com
Studie Locaties
-
-
-
Göttingen, Duitsland, 37075
- Nog niet aan het werven
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Contact:
- Dr. Jana Zschüntzsch
- E-mail: j.zschuentzsch@med.uni-goettingen.de
-
Hoofdonderzoeker:
- Dr. Jana Zschüntzsch
-
-
-
-
-
Roma, Italië, 00165
- Werving
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Contact:
- Dr. Marco Becilli
- Telefoonnummer: +39 0668592739
- E-mail: marco.becilli@opbg.net
-
Hoofdonderzoeker:
- Professor Franco Locatelli
-
-
-
-
-
London, Verenigd Koninkrijk, WC1N 3BG
- Werving
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Contact:
- Dr. Pedro Machado, FRCP, PhD
- Telefoonnummer: 020 3456 7890
- E-mail: uclh.car-ttrials@nhs.net
-
Hoofdonderzoeker:
- Dr. Pedro Machado, FRCP, PhD
-
London, Verenigd Koninkrijk, SE5 9RS
- Werving
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Contact:
- Rheumatology Research Team
- Telefoonnummer: 0628 0207 848 0214
- E-mail: Kch-tr.CRDresearch@nhs.net
-
Hoofdonderzoeker:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Verenigd Koninkrijk, WC1N 3JH
- Werving
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Contact:
- Professor Despina Eleftheriou
- Telefoonnummer: 020 7405 9200
- E-mail: Despina.Eleftheriou@gosh.nhs.uk
-
Hoofdonderzoeker:
- Professor Despina Eleftheriou
-
Manchester, Verenigd Koninkrijk, M13 9WL
- Werving
- Manchester Royal Infirmary - Accepting Adult Patients
-
Contact:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Telefoonnummer: 01612765052
- E-mail: Eleni.Tholouli@mft.nhs.uk
-
Hoofdonderzoeker:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Verenigd Koninkrijk, M6 8HD
- Werving
- Salford Royal Hospital - Accepting Adult Patients
-
Contact:
- Michelle Beswick
- Telefoonnummer: 07759 136787
- E-mail: Rheumatology.Research@nca.nhs.uk
-
Hoofdonderzoeker:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
California
-
Orange, California, Verenigde Staten, 92868
- Werving
- University of California Irvine - Accepting Adult Patients
-
Hoofdonderzoeker:
- Tahseen Mozaffar, MD
-
Contact:
- Alpha Clinic
- Telefoonnummer: 949-824-3990
- E-mail: alphaclinic@uci.edu
-
San Francisco, California, Verenigde Staten, 94158
- Werving
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Contact:
- Zilan Zheng
- Telefoonnummer: 415-353-1301
- E-mail: Zilan.Zheng@ucsf.edu
-
Hoofdonderzoeker:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80046
- Werving
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Hoofdonderzoeker:
- Dr. Kentaro Yomogida, MD
-
Contact:
- Callie Strini - Primary Clinical Research Coordinator
- Telefoonnummer: 720-777-9845
- E-mail: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224
- Werving
- Mayo Clinic Florida - Accepting Adult Patients
-
Contact:
- Gabrielle Pariseau
- Telefoonnummer: 904-953-5549
- E-mail: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Verenigde Staten, 33701
- Werving
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Hoofdonderzoeker:
- Natalie Booth, DO
-
Contact:
- Laura Escobar
- Telefoonnummer: 727-767-2946
- E-mail: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30032
- Werving
- Emory University - Accepting Adult Patients
-
Contact:
- John Varghese
- E-mail: john.varghese@emory.edu
-
Hoofdonderzoeker:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Verenigde Staten, 30029
- Werving
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Hoofdonderzoeker:
- Shanmuganathan Chandrakasan, MD
-
Contact:
- Judson Russell
- Telefoonnummer: 404-785-7263
- E-mail: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Hoofdonderzoeker:
- Dr. George Georges, MD
-
Contact:
- Kaitlin King
- Telefoonnummer: 312-695-0990
- E-mail: autoimmunesct@nm.org
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Hoofdonderzoeker:
- Dr. Iazsmin Ventura, MD
-
Contact:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Telefoonnummer: 773-702-6619
- E-mail: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Onderonderzoeker:
- Dr. Cuoghi Edens, MD, FAAP
-
Contact:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- E-mail: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Contact:
- Tyler Sorensen
- Telefoonnummer: 312-277-6828
- E-mail: tsorensen@luriechildrens.org
-
Hoofdonderzoeker:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- University of Kansas Medical Center - Accepting Adult Patients
-
Contact:
- Samantha Colgan
- Telefoonnummer: 913-945-9938
- E-mail: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20892
- Werving
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Contact:
- Julie Thompson
- Telefoonnummer: 301-480-3191
- E-mail: Julie.thompson@nih.gov
-
Hoofdonderzoeker:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Hoofdonderzoeker:
- Susan Prockop, MD
-
Contact:
- Kyle McBrearty
- Telefoonnummer: 617-355-2780
- E-mail: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48105
- Werving
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Contact:
- Abigail Whalen
- Telefoonnummer: 734-615-4466
- E-mail: abigaiwh@med.umich.edu
-
Hoofdonderzoeker:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55902
- Werving
- Mayo Clinic - Accepting Adult Patients
-
Contact:
- Bridget Neja
- Telefoonnummer: 507-266-9150
- E-mail: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Verenigde Staten, 10021
- Werving
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Contact:
- Janvi Bhatia
- Telefoonnummer: 212-774-2123
- E-mail: bhatiaj@hss.edu
-
Hoofdonderzoeker:
- David R. Fernandez, MD, PhD
-
New York, New York, Verenigde Staten, 10021
- Werving
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Hoofdonderzoeker:
- Jae Park, MD
-
Contact:
- Atifah Osrat
- Telefoonnummer: 646-608-2091
- E-mail: osrata1@mskcc.org
-
The Bronx, New York, Verenigde Staten, 10467
- Werving
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Contact:
- Emily Gillies
- Telefoonnummer: 718-696-2402
- E-mail: egillies@montefiore.org
-
Hoofdonderzoeker:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599
- Werving
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Hoofdonderzoeker:
- Saira Sheikh, MD
-
Contact:
- Leah Luizza
- E-mail: leah.luizza@med.unc.edu
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Hoofdonderzoeker:
- Kaveh Ardalan, MD, MS
-
Contact:
- Lynn Rodgers, MS
- Telefoonnummer: 919-668-2953
- E-mail: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Werving
- Oregon Health & Science University - Accepting Adult Patients
-
Contact:
- Katie Lewis
- Telefoonnummer: 503-908-9724
- E-mail: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Contact:
- CARTintake@chop.edu
- E-mail: CARTintake@chop.edu
-
Hoofdonderzoeker:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15261
- Werving
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Contact:
- Carol Oriss
- E-mail: orissca@upmc.edu
-
Hoofdonderzoeker:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Werving
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Contact:
- Vibha Chauhan, PhD
- Telefoonnummer: 412-692-7924
- E-mail: Vibha.chauhan@chp.edu
-
Hoofdonderzoeker:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Contact:
- Tofi Soneye
- Telefoonnummer: 817-883-4730
- E-mail: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Hoofdonderzoeker:
- Samuel John, MD
-
Contact:
- Dr. Samuel John
- E-mail: dtpteam@childrens.com
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Hospital - Accepting Adult Patients
-
Contact:
- Amelia A. Nounes, MSN, RN, CCRP
- Telefoonnummer: 346-356-3639
- E-mail: aanounes@houstonmethodist.org
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Hoofdonderzoeker:
- Huifang (Linda) Lu, MD
-
Contact:
- Christina Amos Briggs, BSN, RN
- Telefoonnummer: 713-563-5076
- E-mail: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84113
- Werving
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Contact:
- Morgan Badgley - Research Coordinator
- Telefoonnummer: 801-662-4812
- E-mail: morgan.badgley@hsc.utah.edu
-
Hoofdonderzoeker:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Werving
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Contact:
- Dr. Susan Shenoi, MD, MS
- Telefoonnummer: 206-987-2193
- E-mail: susan.shenoi@SeattleChildrens.org
-
Hoofdonderzoeker:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Nog niet aan het werven
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Hoofdonderzoeker:
- Sara Sabbagh, DO
-
Contact:
- Erin Hammelev - Research Coordinator
- Telefoonnummer: 414-337-7064
- E-mail: ehammele@mcw.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andere namen:
|
|
Experimenteel: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andere namen:
|
|
Experimenteel: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Tijdsspanne: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Tijdsspanne: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Tijdsspanne: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Tijdsspanne: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Tijdsspanne: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Tijdsspanne: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tijdsspanne: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tijdsspanne: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tijdsspanne: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie stoel: Medical Director, Cabaletta Bio
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Myositis
- Dermatomyositis
- Auto immuunziekte
- Cellulaire Therapie
- Juveniele Dermatomyositis
- CABA-201
- Anti-CD19 CAR-T-therapie
- Idiopathische inflammatoire myopathie
- Anti-synthetase-syndroom
- Immuungemedieerde necrotiserende myopathie
- Juveniele polymyositis
- Juveniele idiopathische inflammatoire myopathie (JIIM)
- Juveniele myositis
Aanvullende relevante MeSH-voorwaarden
- Musculoskeletale aandoeningen
- Ziekten van het zenuwstelsel
- Spierziekten
- Neuromusculaire aandoeningen
- Bindweefselziekten
- Ziekten van het immuunsysteem
- Huidziektes
- Polymyositis
- Huid- en bindweefselaandoeningen
- Auto-immuunziekten
- Dermatomyositis
- Myositis
- Organische chemicaliën
- Koolwaterstoffen
- Fosforamide mosterd
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Fosforamides
- Organofosforverbindingen
- Cyclofosfamide
- fludarabine
Andere studie-ID-nummers
Andere studie-ID-nummers
- CAB-201-002
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .